Anti-IgE – emerging opportunities for Omalizumab

Bibliography

• Prausnitz C, Kustner H. Studien uber die uberempfindlichkeit. Zentralblat fur Bakteriologie 1921;86:160-9
   Google Scholar
• Johansson SG, Bennich H, Wide L. A new class of immunoglobulin in human serum. Immunology 1968;14(2):265-72
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Gnanakumaran G, Babu KS. Anti-IgE in allergic asthma and rhinitis: an update. Expert Opin Biol Ther 2007;7(11):1739-47
   PubMed Web of Science ®Google Scholar
• Parravicini V, Gadina M, Kovarova M, Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol 2002;3(8):741-8
   PubMed Web of Science ®Google Scholar
• Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, Structure and functions of CD23. Int Rev Immunol 1997;16(1-2):113-28
   PubMedGoogle Scholar
• Poole JA, Meng J, Reff M, Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005;116(4):780-8
   PubMed Web of Science ®Google Scholar
• Van Cauwenberge PB. Nasal sensitization. Allergy 1997;52(33 Suppl):7-9
   PubMedGoogle Scholar
• de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol 1999;103(5 Pt 2):S492-6
   PubMed Web of Science ®Google Scholar
• Gauchat JF, Lebman DA, Coffman RL, Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med 1990;172(2):463-73
   PubMed Web of Science ®Google Scholar
• Presta L, Shields R, O'Connell L, The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269(42):26368-73
   PubMed Web of Science ®Google Scholar
• Presta LG, Lahr SJ, Shields RL, Humanization of an antibody directed against IgE. J Immunol 1993;151(5):2623-32
   PubMed Web of Science ®Google Scholar
• Omalizumab, Xolair, label information. Available from: www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf
   Google Scholar
• Fox JA, Hotaling TE, Struble C, Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279(2):1000-8
   PubMed Web of Science ®Google Scholar
• Liu J, Lester P, Builder S, Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34(33):10474-82
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim JK, Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996;26(3):690-6
   PubMed Web of Science ®Google Scholar
• Mariani G, Strober W. Immunoglobulin metabolism. In: Metzger H, editor. Receptors and the action of antibodies. American Society of Microbiology, Washington DC; 1990. p. 94-177
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. 2007
   Google Scholar
• Bousquet J, Cabrera P, Berkman N, The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302-8
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16
   PubMed Web of Science ®Google Scholar
• Bousquet J, van Cauwenbage P, Khaltaey N. Allergic rhinitis and its impact on asthma (ARIA) workshop report. J Allergy Clin Immunol 2001;108(Suppl):S147-334
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21(1):77-83
   PubMed Web of Science ®Google Scholar
• Adelroth E, Rak S, Haahtela T, Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106(2):253-9
   PubMed Web of Science ®Google Scholar
• Casale TB, Condemi J, LaForce C, Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286(23):2956-67
   PubMed Web of Science ®Google Scholar
• Nayak A, Casale T, Miller SD, Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24(5):323-9
   PubMed Web of Science ®Google Scholar
• Okubo K, Ogino S, Nagakura T, Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006;55(4):379-86
   PubMedGoogle Scholar
• Ogino S, Nagakura T, Okubo K, Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 2009;149(3):239-45
   PubMed Web of Science ®Google Scholar
• Nagakura T, Ogino S, Okubo K, Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2008;38(2):329-37
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Casale T, Townley R, Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(2):160-7
   PubMed Web of Science ®Google Scholar
• Bachert C, Vignola AM, Gevaert P, Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am 2004;24(1):19-43
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709-17
   PubMed Web of Science ®Google Scholar
• Corren J, Shapiro G, Reimann J, Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008;121(2):506-11
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010(8):CD001186
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64(12):1728-36
   PubMed Web of Science ®Google Scholar
• Eckman JA, Sterba PM, Kelly D, Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010;125(4):889-95 e7
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109(2):274-80
   PubMed Web of Science ®Google Scholar
• Rolinck-Werninghaus C, Hamelmann E, Keil T, The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59(9):973-9
   PubMed Web of Science ®Google Scholar
• Kopp MV, Stenglein S, Kamin W, Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007;18(6):523-7
   PubMed Web of Science ®Google Scholar
• Kopp MV, Brauburger J, Riedinger F, The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110(5):728-35
   PubMed Web of Science ®Google Scholar
• Kamin W, Kopp MV, Erdnuess F, Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010;21(1 Pt 2):e160-5
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39(2):271-9
   PubMed Web of Science ®Google Scholar
• Massanari M, Nelson H, Casale T, Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125(2):383-9
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117(1):134-40
   PubMed Web of Science ®Google Scholar
• Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008;63(3):376-8
   PubMed Web of Science ®Google Scholar
• Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007;62(8):963-4
   PubMed Web of Science ®Google Scholar
• Galera C, Soohun N, Zankar N, Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009;19(3):225-9
   PubMed Web of Science ®Google Scholar
• Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44(1 Suppl):S1-S12
   PubMed Web of Science ®Google Scholar
• Lane JE, Cheyney JM, Lane TN, Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54(1):68-72
   PubMed Web of Science ®Google Scholar
• Park SY, Choi MR, Na JI, Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010;22(3):349-52
   PubMed Web of Science ®Google Scholar
• Amrol D. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. South Med J 2010;103(6):554-8
   PubMed Web of Science ®Google Scholar
• Ramirez del Pozo ME, Contreras Contreras E, Lopez Tiro J, Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 2011;21(5):416-17
   PubMed Web of Science ®Google Scholar
• Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 2012;103(7):624-8
   PubMedGoogle Scholar
• Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53(2):338-40
   PubMed Web of Science ®Google Scholar
• Sheinkopf LE, Rafi AW, Do LT, Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29(5):530-7
   PubMed Web of Science ®Google Scholar
• Vigo PG, Girgis KR, Pfuetze BL, Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006;55(1):168-70
   PubMed Web of Science ®Google Scholar
• Belloni B, Ziai M, Lim A, Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120(5):1223-5
   PubMed Web of Science ®Google Scholar
• Velling P, Skowasch D, Pabst S, Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res 2011;16(9):407-10
   PubMed Web of Science ®Google Scholar
• Available from: clinicaltrials.gov [Last accessed September 2011]
   Google Scholar
• Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99(2):190-3
   PubMed Web of Science ®Google Scholar
• Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010;90(4):443-4
   PubMed Web of Science ®Google Scholar
• Metz M, Bergmann P, Zuberbier T, Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008;63(2):247-9
   PubMed Web of Science ®Google Scholar
• Iemoli E, Piconi S, Fusi A, Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010;20(3):252-4
   PubMed Web of Science ®Google Scholar
• Magerl M, Staubach P, Altrichter S, Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010;126(3):665-6
   PubMed Web of Science ®Google Scholar
• Ivyanskiy I, Sand C, Francis ST. Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol 2012;4(1):19-26
   PubMedGoogle Scholar
• Groffik A, Mitzel-Kaoukhov H, Magerl M, Omalizumab -- an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66(2):303-5
   PubMed Web of Science ®Google Scholar
• Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2010;35(4):e127-9
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122(3):569-73
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128(1):202-9 e5
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128(3):567-73; e1
   PubMed Web of Science ®Google Scholar
• Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006;117(6):1415-18
   PubMed Web of Science ®Google Scholar
• Guzelbey O, Ardelean E, Magerl M, Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008;63(11):1563-5
   PubMed Web of Science ®Google Scholar
• Waibel KH, Reese DA, Hamilton RG, Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010;125(2):490-1
   PubMed Web of Science ®Google Scholar
• Duchini G, Baumler W, Bircher AJ, Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 2011;27(6):336-7
   PubMed Web of Science ®Google Scholar
• Metz M, Altrichter S, Ardelean E, Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154(2):177-80
   PubMed Web of Science ®Google Scholar
• Fairley JA, Baum CL, Brandt DS, Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009;123(3):704-5
   PubMed Web of Science ®Google Scholar
• Carter MC, Robyn JA, Bressler PB, Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119(6):1550-1
   PubMed Web of Science ®Google Scholar
• Siebenhaar F, Kuhn W, Zuberbier T, Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 2007;120(1):213-15
   PubMed Web of Science ®Google Scholar
• Buyukozturk S, Gelincik A, Demirturk M, Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 2012;39(5):439-42
   PubMed Web of Science ®Google Scholar
• Nadeau KC, Schneider LC, Hoyte L, Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011;127(6):1622-4
   PubMed Web of Science ®Google Scholar
• Rafi A, Do LT, Katz R, Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010;31(1):76-83
   PubMed Web of Science ®Google Scholar
• Bedoret D, Singh AK, Shaw V, Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol 2012;5(3):267-76
   PubMed Web of Science ®Google Scholar
• Leung DY, Sampson HA, Yunginger JW, Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348(11):986-93
   PubMed Web of Science ®Google Scholar
• Sampson HA, Leung DY, Burks AW, A Phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011;127(5):1309-10 e1
   PubMed Web of Science ®Google Scholar
• Savage JH, Courneya JP, Sterba PM, Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012;130(5):1123-9 e2
   PubMed Web of Science ®Google Scholar
• Agarwal S, Gawkrodger DJ. Latex allergy: a health care problem of epidemic proportions. Eur J Dermatol 2002;12(4):311-15
   PubMed Web of Science ®Google Scholar
• Sussman GL, Beezhold DH, Kurup VP. Allergens and natural rubber proteins. J Allergy Clin Immunol 2002;110(2 Suppl):S33-9
   PubMed Web of Science ®Google Scholar
• Leynadier F, Doudou O, Gaouar H, Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004;113(2):360-1
   PubMed Web of Science ®Google Scholar
• Stone KD, Prussin C. Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases. Clin Exp Allergy 2008;38(12):1858-65
   PubMed Web of Science ®Google Scholar
• Foroughi S, Foster B, Kim N, Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007;120(3):594-601
   PubMed Web of Science ®Google Scholar
• Rocha R, Vitor AB, Trindade E, Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 2011
   PubMed Web of Science ®Google Scholar
• Williams PB, Sheppard JD Jr. Omalizumab: a future innovation for treatment of severe ocular allergy? Expert Opin Biol Ther 2005;5(12):1603-9
   PubMed Web of Science ®Google Scholar
• van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007;62(3):276-7
   PubMed Web of Science ®Google Scholar
• Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008;43(6):607-10
   PubMed Web of Science ®Google Scholar
• Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009;44(5):516
   PubMed Web of Science ®Google Scholar
• Lebecque P, Leonard A, Argaz M, Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep 2009; doi:10.1136/bcr.07.2008.0379
   Google Scholar
• Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008;43(12):1249-51
   PubMed Web of Science ®Google Scholar
• Randhawa I, Chin T, Nussbaum E. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009;46(5):445-7
   PubMed Web of Science ®Google Scholar
• Lin RY, Sethi S, Bhargave GA. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J Asthma 2010;47(8):942-5
   PubMed Web of Science ®Google Scholar
• Collins J, Devos G, Hudes G, Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 2012;5:65-70
   PubMedGoogle Scholar
• Sastre I, Blanco J, Mata H, A case of allergic bronchopulmonary aspergillosis treated with omalizumab. J Investig Allergol Clin Immunol 2012;22(2):145-7
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007;144(2):155-8
   PubMed Web of Science ®Google Scholar
• Pabst S, Tiyerili V, Grohe C. Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax 2008;63(8):747-8
   PubMed Web of Science ®Google Scholar
• Cazzola M, Mura M, Segreti A, Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome? Allergy 2009;64(9):1389-90
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Wong DA, Miller MK, Churg-strauss syndrome in patients treated with omalizumab. Chest 2009;136(2):507-18
   PubMed Web of Science ®Google Scholar
• Jones JD, Marney SR Jr, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 2008;101(5):550-1
   PubMed Web of Science ®Google Scholar
• Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009;102(3):257-8
   PubMed Web of Science ®Google Scholar
• Pitt TJ, Cisneros N, Kalicinsky C, Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol 2010;126(2):415-16; author reply 6
   PubMed Web of Science ®Google Scholar
• Demirturk M, Gelincik A, Colakoglu B, Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 2012;39(6):552-4
   PubMed Web of Science ®Google Scholar
• Douglass JA, Carroll K, Voskamp A, Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010;65(7):926-7
   PubMed Web of Science ®Google Scholar
• Bobolea I, Barranco P, Fiandor A, Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2010;20(5):448-9
   PubMed Web of Science ®Google Scholar
• Ferguson BJ, Otto BA, Pant H. When surgery, antibiotics, and steroids fail to resolve chronic rhinosinusitis. Immunol Allergy Clin North Am 2009;29(4):719-32
   PubMed Web of Science ®Google Scholar
• Bard S, Paravisini A, Aviles-Izquierdo JA, Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008;144(12):1662-3
   PubMed Web of Science ®Google Scholar
• Lee J, Doggweiler-Wiygul R, Kim S, Is interstitial cystitis an allergic disorder?: a case of interstitial cystitis treated successfully with anti-IgE. Int J Urol 2006;13(5):631-4
   PubMed Web of Science ®Google Scholar
• Pinto JM, Mehta N, DiTineo M, A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010;48(3):318-24
   PubMed Web of Science ®Google Scholar
• Chularojanamontri L, Wimoolchart S, Tuchinda P, Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol 2009;27(4):233-6
   PubMed Web of Science ®Google Scholar
• Aksu K, Kurt E. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol Immunopathol (Madr) 2012; http://dx.doi.org/10.1016/j.aller.2012.02.005
   Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ, Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med 2013;368(10):924-35
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-190
   PubMed Web of Science ®Google Scholar
• Milgrom H, Berger W, Nayak A, Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36
   PubMed Web of Science ®Google Scholar
• Milgrom H, Fick RB, Jr., Su JQ, Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999;341(26):1966-73
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701-8
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61
   PubMed Web of Science ®Google Scholar